[go: up one dir, main page]

MX2017010037A - Metodos de tratamiento de enfermedades inflamatorias. - Google Patents

Metodos de tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2017010037A
MX2017010037A MX2017010037A MX2017010037A MX2017010037A MX 2017010037 A MX2017010037 A MX 2017010037A MX 2017010037 A MX2017010037 A MX 2017010037A MX 2017010037 A MX2017010037 A MX 2017010037A MX 2017010037 A MX2017010037 A MX 2017010037A
Authority
MX
Mexico
Prior art keywords
methods
inflammatory diseases
treating inflammatory
spa
diseases
Prior art date
Application number
MX2017010037A
Other languages
English (en)
Other versions
MX392789B (es
Inventor
Bettina Galler Annette
John Padula Steven
Arndt Matthias
Aslanyan Stella
Ruth Flack Mary
Lalovic Bojan
Russell Scholl Paul
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2017010037A publication Critical patent/MX2017010037A/es
Publication of MX392789B publication Critical patent/MX392789B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular enfermedades inflamatorias, tales como psoriasis, artritis psoriásica o espondiloartritis axial (espinal) (ax-SpA), que incluye la espondilitis anquilosante y la ax-SpA no radiográfica, que utilizan anticuerpos anti-IL-23A.
MX2017010037A 2015-02-04 2016-02-02 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias MX392789B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US201562235631P 2015-10-01 2015-10-01
PCT/US2016/016061 WO2016126638A1 (en) 2015-02-04 2016-02-02 Methods of treating inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2017010037A true MX2017010037A (es) 2018-05-15
MX392789B MX392789B (es) 2025-03-21

Family

ID=55453266

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017010037A MX392789B (es) 2015-02-04 2016-02-02 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias
MX2022006573A MX2022006573A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2022006575A MX2022006575A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022006573A MX2022006573A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2022006575A MX2022006575A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.

Country Status (14)

Country Link
US (1) US12441785B2 (es)
EP (2) EP4670787A2 (es)
JP (7) JP6758304B2 (es)
KR (2) KR20240158362A (es)
CN (2) CN107206081A (es)
AU (3) AU2016215535B2 (es)
BR (1) BR112017014684A2 (es)
CL (1) CL2017001960A1 (es)
EA (1) EA201791734A1 (es)
IL (4) IL307578A (es)
MX (3) MX392789B (es)
PH (1) PH12017501378A1 (es)
SG (2) SG10202103879YA (es)
WO (1) WO2016126638A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
PH12017500370B1 (en) 2014-09-03 2023-12-06 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
CA3018794A1 (en) * 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Use of il-23 antibodies for treating generalized pustular psoriasis
JP2020500152A (ja) * 2016-09-30 2020-01-09 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
CN106778030B (zh) * 2017-01-10 2023-04-07 广州和康医疗技术有限公司 一种强直性脊柱炎病情监测管理系统及其监测管理方法
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CN111378045B (zh) 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
EP4469154A1 (en) * 2022-01-25 2024-12-04 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with plaque psoriasis of the scalp
TW202511290A (zh) * 2023-09-07 2025-03-16 大陸商信達生物製藥(蘇州)有限公司 一種重組抗IL-23p19抗體治療中重度銀屑病的方法
TW202540171A (zh) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Il-23抗體組合物及使用方法

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
ATE216590T1 (de) 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
WO1999054357A1 (en) 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
US6367172B2 (en) 1999-07-02 2002-04-09 Bbc International Ltd. Flex sole
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PL209128B1 (pl) 2000-05-10 2011-07-29 Schering Corp Białko receptora spokrewnionego z receptorami cytokin oraz związane z nim produkty, sposoby i zastosowania
JPWO2003034818A1 (ja) 2001-10-24 2005-02-10 中外製薬株式会社 Sgrf遺伝子改変非ヒト動物
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
MXPA05004512A (es) 2002-10-30 2005-07-26 Genentech Inc Inhibicion de la produccion de il-17.
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
WO2005005612A2 (en) 2003-07-01 2005-01-20 University Of Virginia Patent Foundation Tag-1 and tag-2 proteins and uses thereof
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005079837A1 (en) 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング コーポレイション 皮膚の炎症を予測するためのil−17発現の使用;処置方法
US20060084145A1 (en) 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI363091B (en) 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
AU2006265898A1 (en) 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the IL-12 family of cytokines
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EP1977007A4 (en) 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
CN101389351B (zh) 2005-12-29 2012-10-10 森托科尔公司 人抗il-23抗体、组合物、方法和用途
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007261019A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
CL2008000058A1 (es) 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
US20080200591A1 (en) 2007-02-15 2008-08-21 Isao Noda Melt Processable Reactive Pellets Capable of Forming Ester Condensates and Process for Forming Melt Processable Reactive Pellets
KR20090110349A (ko) 2007-02-16 2009-10-21 와이어쓰 소르비톨을 함유하는 단백질 제제
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
US20100135998A1 (en) 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
SI2197903T1 (sl) 2007-09-04 2015-02-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer 6011 Izbris v obmoäśju ii pseudomonas eksotoksina a, ki zniĺ˝uje ne-specifiäśno toksiäśnost
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2212442A1 (en) 2007-10-26 2010-08-04 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
KR20110096553A (ko) 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP5934652B2 (ja) 2009-11-24 2016-06-15 アルダーバイオ ホールディングス エルエルシー Il−6に対する抗体およびその使用
CN102695465A (zh) 2009-12-02 2012-09-26 斯帕泰克医疗股份有限公司 结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
WO2011103105A1 (en) 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
CN102946861B (zh) 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
CA2798742A1 (en) 2010-06-15 2011-12-22 Celgene Corporation Biomarkers for the treatment of psoriasis
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
AU2011282476B2 (en) 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
WO2014004436A2 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EA201591579A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения болезни крона при помощи анти-il-23 антитела
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
PH12017500370B1 (en) 2014-09-03 2023-12-06 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
KR20170135972A (ko) 2015-04-14 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 질환을 치료하는 방법
EA201890360A1 (ru) 2015-07-23 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
CA3018794A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Use of il-23 antibodies for treating generalized pustular psoriasis
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
EP3500588A1 (en) 2016-08-17 2019-06-26 Boehringer Ingelheim International GmbH Process for the preparation of highly concentrated liquid formulations containing biomolecules
EP3526252A2 (en) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Methods of treating diseases with il-23a antibody
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
JP7090014B2 (ja) * 2018-11-07 2022-06-23 株式会社ミツバ ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
IL319239A (en) 2022-10-21 2025-04-01 Chong Kun Dang Pharmaceutical Corp Stable antibody preparation

Also Published As

Publication number Publication date
SG10202103879YA (en) 2021-05-28
NZ733136A (en) 2024-04-26
AU2016215535A1 (en) 2017-07-13
JP2022081644A (ja) 2022-05-31
JP2025060797A (ja) 2025-04-10
JP2020125338A (ja) 2020-08-20
JP2025060798A (ja) 2025-04-10
MX2022006573A (es) 2022-07-11
JP7042298B2 (ja) 2022-03-25
JP2018505882A (ja) 2018-03-01
EP4670787A2 (en) 2025-12-31
JP2020125340A (ja) 2020-08-20
PH12017501378A1 (en) 2018-01-08
CL2017001960A1 (es) 2018-04-20
AU2021286378B2 (en) 2025-03-13
KR20240158362A (ko) 2024-11-04
IL321788A (en) 2025-08-01
AU2016215535B2 (en) 2021-09-16
JP7044824B2 (ja) 2022-03-30
IL307578A (en) 2023-12-01
US12441785B2 (en) 2025-10-14
BR112017014684A2 (en) 2018-01-09
IL253118A0 (en) 2017-08-31
CN107206081A (zh) 2017-09-26
EP3253794A1 (en) 2017-12-13
WO2016126638A1 (en) 2016-08-11
AU2021286378A1 (en) 2022-01-20
CA2972995A1 (en) 2016-08-11
JP7042297B2 (ja) 2022-03-25
AU2025204286A1 (en) 2025-07-03
KR20170120616A (ko) 2017-10-31
IL323562A (en) 2025-11-01
CN113559258A (zh) 2021-10-29
MX2022006575A (es) 2022-07-11
EA201791734A1 (ru) 2018-01-31
US20160222102A1 (en) 2016-08-04
JP2020125339A (ja) 2020-08-20
SG11201705728RA (en) 2017-08-30
MX392789B (es) 2025-03-21
JP6758304B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
MX2017010037A (es) Metodos de tratamiento de enfermedades inflamatorias.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
MX372669B (es) Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2016006232A (es) Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
CL2016002281A1 (es) Anticuerpos de il-21
CL2021002815A1 (es) Usos de anticuerpos anti-il-17a/f (divisional 2018-01135)
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
MX2019000539A (es) Anticuerpos anti-il-22r.
MX2016012620A (es) Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).
PH12017501872A1 (en) Methods of treating diseases
BR112017025264A2 (pt) tratamento de prurido
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau